Imaging in Targeted Radiopharmaceuticals

The gold standard among PET radiopharmaceuticals in the clinic is still 18F-FDG. This radiotracer visualises a basic biochemical function of most living cells, glucose consumption, which is up or down regulated in certain disease processes. However, FDG has known limitations, mainly caused by the non-specificity of metabolic changes. This results in a need for the development of alternative radiopharmaceuticals that are able to target specific receptors, cells, etc. In addition, radioligand therapy is more and more recognized as a prominent treatment strategy where PET radiotracers can assess drug-target expression in real time and identify potential responders. There are several reasons why the use of PET imaging in the development of targeted radiopharmaceuticals offers many advantages. The following points clearly demonstrate that PET imaging is an ideal, cost-efficient tool to follow up disease/therapy progression when studying the efficacy of newly developed targeted radiotherapies.

Please enter your details below to gain on-demand access to this Document.